ModernMedicine Resource Center More Topics

Therapeutic Considerations for Psoriasis

A noteworthy margin of error in psoriasis?Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.
Restarting TNFi treatment after a break proves beneficial in psoriasisSwitching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Hard-to-treat psoriasis cases respond to secukinumabSecukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Promising results for risankizumab continue in phase 3 trialsPhase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Psoriasis patients have a heightened risk of malignant lymphomaPatients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.
Caffeine can reduce inflammation in patients with eczema and psoriasisAdding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.